Clinical Trial

A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

Dimensions: NCT03024996

Investigators

Affiliations

Organisations

Sponsors/collaborators

Abstract

This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.

Methods

Condition: Renal Cell Carcinoma

Intervention: Placebo matching to atezolizumab q3w

Recruitment information

Gender: All

Trial period

2017-2024

Phase

Phase 3

Research Categories

Main Subject Area

Fields of Research

External sources

Access at Registry